Biogen Message Board - Msg: 16625757

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biogen

BIIB 151.47

-1.8%

Nov 3 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Harold Engstrom who started this subject	11/8/2001 1:18:30 AM
From: aknahow	of 1686

On November 1, BGEN indicated that Amevive would be a $500 million dollar drug three years after launch. The timeline for the launch has also been pushed back from earlier expectations. "PSORIASIS DRUG SEEN LAUNCHING BY Q1 2003 Biogen said it expects its psoriasis drug Amevive to be launched by the end of 2002 or the first quarter of 2003, confirming fears of some analysts that the expected 2002 launch might be delayed into 2003. Company officials predicted the psoriasis drug, if approved, could achieve annual sales of $500 million within three years. Biogen filed in August for U.S. and European marketing approval of Amevive, for treatment of moderate-to-severe chronic psoriasis."

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next